Dan Gusenleitner is a Director of Computational Biology with a passion for enhancing cancer drug development through data-driven approaches. Currently at Bayer, Dan leads initiatives in oncology data strategy and decision-making frameworks. Previously, Dan held significant roles at Novartis and Mercy BioAnalytics, focusing on biomarker analyses and computational target discovery. Dan's educational background includes a PhD in Computational Biology from Boston University, supported by multiple master's degrees in Bioinformatics and Biomedical Informatics. Personal experiences with cancer inform Dan's commitment to advancing personalized medicine.
This person is not in the org chart
This person is not in any teams
This person is not in any offices